Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Portfolio Pulse from
Spero Therapeutics announced interim leadership changes with Esther Rajavelu as Interim CEO and Frank Thomas as Chairman, following a Wells Notice from the SEC. The Phase 3 PIVOT-PO trial of Tebipenem HBr has reached over 60% enrollment, with completion expected in 2H 2025. The company's cash runway extends into mid-2026.
January 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Spero Therapeutics has appointed interim leadership following a Wells Notice from the SEC. The Phase 3 trial of Tebipenem HBr is progressing well, with over 60% enrollment. The company's cash position is stable, with a runway into mid-2026.
The leadership changes and SEC Wells Notice could create uncertainty, but the progress in the Phase 3 trial and stable cash position are positive. The net impact on the stock price is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100